Guidance on Labelling Requirements of Product Code, Unique Donation Identifier and Unique Recipient Identifier for Advanced Therapy Products

Version 1.0
Pharmacy and Poisons Board of Hong Kong
1. **Introduction**

1.1 Advanced Therapy Products (ATPs) are innovative medical products based on genes, cells and tissues. Due to their complicated nature, safety and quality issues of the cells and tissues used for the manufacture of ATPs may only be identified after processing, supply or administration to patients in some occasions. Additional health information about the donor that may imply safety and quality issues of ATPs are sometimes known late after the donation, processing or supply of the cells and tissues products. As such, an effective and efficient traceability system covering from the donation through processing to the end use is essential to allow determination of ATPs and patients potentially affected for the necessary patient follow-up and recall of the affected ATPs in these situations.

1.2 The traceability system is inseparable from the coding system for cells and tissues. The coding system bearing information of donation and cells and tissue types facilitates tracing of the cells and tissues from the donor to the recipient and vice versa. Labelling of such codes on the packaging of ATPs and recording such information in the manufacturing and supply records permit rapid identification of affected cells, tissues and ATPs as well as the patients affected in case of any safety and quality issues identified.

1.3 For autologous ATPs, administration of the correct product to the intended recipient is crucial in terms of safety and efficacy. Labelling of the unique recipient identifier on the packaging of these products permits healthcare professionals to check the correct product to be administered to the correct intended recipient before product administration and hence prevent any medical incidents owing to product mix-up and administration of wrong product.

1.4 Under the Pharmacy and Poisons Ordinance, Cap. 138 (PPO), ATPs are regulated as a specific subset of pharmaceutical products. An ATP means any of the following products that is for human use—
(a) a gene therapy product;
(b) a somatic cell therapy product;
(c) a tissue engineered product.

1.5 Relevant definitions of pharmaceutical product, ATP, gene therapy product, somatic cell therapy product and tissue engineered product are set out in section 2 of the PPO.

1.6 According to regulation 31(1) of the Pharmacy and Poisons Regulations, Cap. 138A (PPR), a licensed manufacturer shall label the container of the ATP with the following particulars—

(a) the appropriate designation of each active ingredients/constituents of the product;
(b) the quantitative particulars of those ingredients or constituents;
(c) the name and address of the manufacturer;
(d) the number of the certificate issued under regulation 36(5) if the ATP is registered under regulation 36 (i.e. the registration number of registered pharmaceutical product);
(e) the batch number;
(f) the expiry date;
(g) (i) the product code and the unique donation identifier; and
   (ii) the unique recipient identifier and “For autologous use only” or “只供自體使用” if the product is for autologous use only.

1.7 According to regulation 38(1) of the PPR, no person shall sell or supply a medicine unless it is labelled as required under the regulation 31 of the PPR.
2. Purpose and Scope

2.1 This guidance aims to provide information to licensed manufacturers and licensed wholesale dealers on the requirements of assigning the Product Code, Unique Donation Identifier and Unique Recipient Identifier for labelling of ATPs stated under regulation 31(1)(g)(i) and (ii) of the PPR. It also introduces two internationally recognized labelling systems – the ISBT 128 standard and the Single European Code, that could be adopted for assigning the Product Code and Unique Donation Identifier for ATPs containing or consisting of human cells or tissues.

2.2 For labelling requirements stated under regulation 31(1)(a) to (f) of the PPR and other additional labelling requirements, please refer to ‘Guidelines on the Labelling of Pharmaceutical Products’ published by the Drug Office of the Department of Health.

2.3 This guidance is applicable to ATPs manufactured locally or imported for local sale or distribution.

3. Internationally Recognized Systems

3.1 ISBT 128 standard and Single European Code (SEC) are two widely accepted coding systems for human cells and tissues. Both systems include two components – coding for identification of the cell and tissue type and coding for identification of the donation – which could be used to facilitate traceability of the cells and tissues from donation to products, and vice versa.

3.2 Either one of the above systems could be used in labelling ATPs containing or consisting of human cells or tissues to meet the requirements of Product Code and Unique Donation Identifier required under regulation 31(1)(g)(i) of the PPR.

3.3 If the ATPs containing or consisting of human cells or tissues are not labelled in accordance with one of the above systems, Product Code and Unique Donation Identifier could be assigned in accordance with section 4 and section 5 of this guidance respectively.

3.4 Since both the above systems are applicable to human cells and tissues only, for ATPs that do not contain and consist of any human cells or tissues, the product should be labelled with the following particulars in order to meet the Product Code and Unique Donation Identifier requirement under regulation 31(1)(g)(i) of the PPR –

(a) product name;

(b) international non-proprietary name (INN), if any; and

(c) for ATPs containing or consisting of animal cells or tissues, information reflecting the animal species, the country of origin and the types of cells or tissues that they contain or consist of.
**ISBT 128 Standard**

3.5 ISBT 128 (Information Standard for Blood and Transplant) standard is an international standard for the terminology, identification, coding and labelling of products of human origin (including blood, cell, tissue, milk, and organ products), which is registered and licensed for use by the International Council for Commonality in Blood Banking Automation (ICCBBA). The ISBT 128 standard includes a Donation Identification Number (DIN) and a product code on the label.

3.6 DIN of the ISBT 128 standard provides unique identification for every single donation or pooled product made by ISBT 128 licensees worldwide. DIN is a 13-character identifier built up from three elements – the facility identification number; the year in which the DIN is assigned by the facility; and the sequence number assigned and maintained by the facility for each single donation.

Example of DIN is as follow:

```
A9999 20 123456 8 K
```

3.7 Product code of the ISBT 128 standard provides a comprehensive description of the product. The product code consists of an 8-character sequence built up from three elements, a product description code, a collection type code and a division code.
Example of a product code is as follow:

![Product Code Diagram]

3.8 Details and guidance documents of the ISBT 128 standard can be found in the ICCBBA website at:

https://www.iccbba.org/

Single European Code

3.9 SEC is a unique identifier applied to cells and tissues distributed in the European Union (EU). SEC is a coding system used in the EU for human cells and tissues intended for human application, to ensure traceability of cells and tissues from the donor to the recipient and vice versa. The SEC consists of a donation identification sequence (SEC-DI) and a product identification sequence (SEC-PI).

3.10 SEC-DI is the first part of the SEC and it provides unique identification of every single donation or pooled product in accredited, designated, authorised, or licensed tissue establishments in the EU. SEC-DI is a 21-character identifier built up from two elements – an EU tissue establishment code (consisting of an ISO country code and a tissue establishment number) and a unique donation number attributed to each single donation.
Example of a SEC-DI is as follow:

3.11 SEC-PI is the second part of the SEC and it provides identification for the specific type of cell and tissue. SEC-PI is a 19-character sequence built up from three elements – the product code, the split number and the expiry date of the product.

Example of a SEC-PI is as follow:

3.12 Details of SEC can be found in the following webpage:

https://ec.europa.eu/health/blood_tissues_organs/tissues/single_european_code_en
4. Requirements of Product Code

4.1 Product Code is a set of coding sequence for identification of cell and tissue types that an ATP contains or consists of. If neither ISBT 128 standard nor SEC is adopted for labelling the ATPs containing or consisting of human cells or tissues, a set of coding sequence should be assigned according to this section and labelled on the product as Product Code.

4.2 This section is applicable to ATPs containing or consisting of human cells or tissues only; for ATPs that do not contain or consist of any human cells or tissues, the product should be labelled according to paragraph 3.4 in order to meet the Product Code requirement under regulation 31(1)(g)(i) of the PPR.

4.3 The Product Code consists of two parts – the ‘Product Coding System Identifier’ and the ‘Product Number’. The structure and the format of the Product Code are as follows:

<table>
<thead>
<tr>
<th>Product Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Coding System Identifier</td>
</tr>
<tr>
<td>1 character (alphabetic)</td>
</tr>
</tbody>
</table>

4.4 Currently there are three product coding systems available globally which are widely used for describing human cells and tissues. They are the ISBT 128 standard product code by the ICCBBA, the Eurocode and the EU Tissue and Cell Product Compendium (EUTC). The register of all available types of cells and tissues, and their respective product number under these three product coding systems can be found in the website named EU Coding Platform: [https://webgate.ec.europa.eu/eucoding](https://webgate.ec.europa.eu/eucoding)

One of the three coding systems should be adopted for assigning the Product Code for ATPs supplied in Hong Kong.
4.5 Product Coding System Identifier is a 1-alphabetic character indicating the coding system adopted for labelling the ATPs supplied in Hong Kong of which—

(a) “A” is assigned to the ISBT 128 standard product code;

(b) “B” is assigned to the Eurocode; and

(c) “E” is assigned to the EUTC.

4.6 Product Number is 7-alphanumeric characters revealing the type of cells or tissues that an ATP contains or consists of. The most appropriate product number must be chosen from the adopted coding system to describe the type of cells or tissues that an ATP contains or consists of. If the product number has less than 7 characters, it should be padded with leading zeros.

4.7 For example, an ATP containing cryopreserved hematopoietic progenitor cell isolated from bone marrow, the product codes of the same ATP using different coding systems are as follow:

(a) Product code labelled with the ISBT 128 standard product code

<table>
<thead>
<tr>
<th>Product Coding System Identifier (For ISBT 128 standard)</th>
<th>Product Number (ISBT 128 standard product description code padded to seven characters with two leading zeros)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>00S1122</td>
</tr>
</tbody>
</table>

Product coding system identifier “A” corresponds to the ISBT 128 standard product code and “S1122” corresponds to cryopreserved hematopoietic progenitor cell isolated from bone marrow under the ISBT 128 standard product code. Since the product number “S1122” has less than 7 characters, it should be padded with leading zeros.

---

2 Product number for each coding system was obtained from database on the EU Coding Platform website: [https://webgate.ec.europa.eu/eucoding](https://webgate.ec.europa.eu/eucoding)
and becomes “00S1122”.

(b) Product code labelled with the Eurocode

<table>
<thead>
<tr>
<th>Product Code: B0460234</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Coding System Identifier</td>
</tr>
<tr>
<td>(For Eurocode)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>B</td>
</tr>
<tr>
<td>Product Number</td>
</tr>
<tr>
<td>(Eurocode padded to seven characters with a leading zero)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>0460234</td>
</tr>
</tbody>
</table>

Product coding system identifier “B” corresponds to the Eurocode and “460234” corresponds to cryopreserved hematopoietic progenitor cell isolated from bone marrow under the Eurocode. Since the product number “460234” has less than 7 characters, it should be padded with a leading zero and becomes “0460234”.

(c) Product code labelled with the EUTC

<table>
<thead>
<tr>
<th>Product Code: E0000078</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Coding System Identifier</td>
</tr>
<tr>
<td>(For EUTC)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>E</td>
</tr>
<tr>
<td>Product Number</td>
</tr>
<tr>
<td>(EUTC Code padded to seven characters with five leading zeros)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>0000078</td>
</tr>
</tbody>
</table>

Product coding system identifier “E” corresponds to the EUTC and “78” corresponds to hematopoietic progenitor cell isolated from bone marrow under the EUTC. Since the product number “78” has less than 7 characters, it should be padded with leading zeros and becomes “0000078”.

4.8 Subject to consideration and approval by the respective committees of the Pharmacy and Poisons Board, the requirement of product code may be deemed to have fulfilled if an ATP, that is not labelled with the product code assigned according to section 3 or 4 of this guidance, is labelled with sufficient information that specifically identifies the types of cells or tissues that the ATP contains or consists of.
5. Requirements of Unique Donation Identifier

5.1 Unique Donation Identifier (UDI) is a unique sequence attributed to the specific donation of the cells or tissues for unique identification. If neither ISBT 128 standard nor SEC is adopted for labelling the ATPs containing or consisting of human cells or tissues, a set of coding sequence should be assigned according to this section and labelled on the product as UDI.

5.2 This section is applicable to ATPs containing human cells or tissues only; for ATPs that do not contain or consist of any human cells or tissues, the product should be labelled according to paragraph 3.4 in order to meet the UDI requirement under regulation 31(1)(g)(i) of the PPR.

5.3 For human cells or tissues obtained from a tissue establishment in the EU and already assigned with a SEC (or SEC-DI), the SEC-DI part of that SEC could be adopted as the UDI of the ATPs manufactured from them. For details of SEC-DI, please refer to paragraph 3.10 of this guidance.

5.4 For human cells or tissues without any assigned SEC (or SEC-DI), for example, those obtained from a non-European country or collected locally, the ISBT 128 standard should be adopted. The DIN part of the ISBT 128 standard of those cells or tissues should be labelled on the ATPs manufactured from them as an UDI. For details of DIN, please refer to paragraph 3.6. If the human cells or tissues obtained has already been assigned with a DIN of the ISBT 128 standard, this DIN could be used and labelled on the ATPs manufactured from them as an UDI. For human cells or tissues without any assigned DIN of the ISBT 128 standard, licensed manufacturers should assign a DIN or SEC-DI to the cells or tissues obtained according to ISBT 128 standard or SEC (if applicable) respectively. Registration is required for a facility to assign ISBT 128 standard codes and the details can be found in the
ICCBA website:
https://www.iccbba.org/

5.5 If licensed manufacturers pool the human cells or tissues labelled with different DINs of the ISBT 128 standard or SEC-DIs, the licensed manufacturers should assign an UDI using the ISBT 128 standard to the ATPs manufactured from those pooled cells or tissues. The licensed manufacturers must ensure that individual donation information remains traceable after the new UDI has been assigned.

5.6 Licensed manufacturers should ensure that the facility from where the human cells or tissues are obtained implements a system enabling the tracing of the following donation information in case a particular UDI is provided—

- name and address of the donation site
- identifier of the donor
- date of donation
- types of cells or tissues donated
5.7 Examples of UDI are as follows:

(a) UDI obtained from an ISBT 128 standard label

(b) UDI obtained from an SEC label
6. Requirements of Unique Recipient Identifier for Autologous Advanced Therapy Products

6.1 According to regulation 31(1)(g)(ii) of the PPR, an ATP for autologous use should be labelled with a Unique Recipient Identifier (URI).

6.2 The URI is a combination of recipient information sufficient for healthcare professionals to verify the identity of the intended recipient of the product. The URI should consist of at least two sets of information including:
   • the recipient’s surname followed by initials of the first name
     plus one of the following –
     o the month and year of birth of the recipient
     o any other numeric or alphanumerical number/sequence that is referring to the recipient (e.g. Part of recipient's hospital number/medical record number)

6.3 For example, the URI on the label of an autologous ATPs for a recipient named “Chan Tai Man” with the date of birth “02/01/1960” can be as follow:

   Name of Recipient: ChanTM
   Month and Year of Birth: 01/1960

6.4 Licensed manufacturers and licensed wholesale dealers should ensure that healthcare professionals who use the ATPs fully understand how to interpret and use the recipient information contained in the URI to verify the identity of the recipient.

6.5 In addition, licensed manufacturers and licensed wholesale dealers should comply with the requirements in the Personal Data (Privacy) Ordinance, Cap. 486 (PDPO) when handling personal data. In case of any doubt, the PDPO should be consulted.
Document Information

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Description of Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>1 August 2021</td>
<td>(First version issued in June 2021)</td>
</tr>
</tbody>
</table>

[End of Document]